Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects

Published
03 Apr 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$94.83
76.3% undervalued intrinsic discount
08 Aug
US$22.47
Loading
1Y
35.0%
7D
-3.4%

Author's Valuation

US$94.8

76.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 46%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 3.50%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 15%

AnalystConsensusTarget has increased revenue growth from -25.3% to -16.0%, decreased future PE multiple from 149.9x to 100.1x and increased shares outstanding growth rate from 0.0% to 0.0%.